Tenofovir and Bone Health

Overview

Journal Curr Opin HIV AIDS

Specialty Infectious Diseases

Date 2016 Feb 10

PMID 26859637

Citations 67

Authors

Philip M Grant

Aoife G Cotter

Affiliations

Soon will be listed here.

Abstract

Purpose Of Review: With continued improvements to the antiviral efficacy and tolerability of antiretroviral therapy, long-term safety of antiretroviral therapy has become paramount. Low bone mineral density and fragility fractures are more common in HIV-infected individuals than in the general population. The aims of this review are to describe potential mechanisms underlying the adverse effects of tenofovir on bone, clinical studies of tenofovir disoproxil fumarate (TDF) and bone, and more recent bone data on tenofovir alafenamide.

Recent Finding: Several studies have demonstrated an approximately 1-3% greater bone mineral density loss with TDF compared with other agents. Recent studies with tenofovir alafenamide have shown improved bone (and renal) safety with similar virologic efficacy when compared to TDF.

Summary: Given these findings, TDF-containing regimens may be gradually replaced with non-TDF containing regimens for the treatment of HIV infection, especially in those at higher risk for fragility fracture.

Citing Articles

Urgent focus on enhanced recovery after surgery of AIDS patients with limb fractures.

Li K, Zhang Q Bone Joint Res. 2024; 13(11):647-658.

PMID: 39530173 PMC: 11555538. DOI: 10.1302/2046-3758.1311.BJR-2024-0247.R1.

Building Metabolically Stable and Potent Anti-HIV Thioether-Lipid Analogues of Tenofovir Exalidex: A thorough Pharmacological Analysis.

DErasmo M, Sharma S, Pribut N, Basson A, Dasari M, Bartsch P J Med Chem. 2024; 67(20):18204-18220.

PMID: 39411803 PMC: 11513920. DOI: 10.1021/acs.jmedchem.4c01510.

Markers of Maternal Bone and Renal Toxicity Through 50 Weeks Postpartum: IMPAACT 2010 (VESTED) Trial.

Masheto G, Brummel S, Ziemba L, Shepherd J, Mbengeranwa T, Igawa L J Acquir Immune Defic Syndr. 2024; 97(2):172-179.

PMID: 39250651 PMC: 11384307. DOI: 10.1097/QAI.0000000000003478.

The impact of HIV infection on skeletal maturity in peripubertal children in Zimbabwe: a cross-sectional study.

Kowo-Nyakoko F, Gregson C, Westbury L, Madanhire T, Offiah A, Micklesfield L BMC Pediatr. 2024; 24(1):480.

PMID: 39068422 PMC: 11282653. DOI: 10.1186/s12887-024-04965-y.

Tenofovir-Associated Kidney Dysfunction and Bone Fracture: A Case Report and Literature Review.

Athish K, Nayak Rao S, Marimuthu V, Krishna V, Arun A Cureus. 2024; 16(6):e61562.

PMID: 38962632 PMC: 11220731. DOI: 10.7759/cureus.61562.

References

Nelson M, Katlama C, Montaner J, Cooper D, Gazzard B, Clotet B . The safety of tenofovir disoproxil fumarate for the treatment of HIV infection in adults: the first 4 years. AIDS. 2007; 21(10):1273-81. DOI: 10.1097/QAD.0b013e3280b07b33. View

Mills A, Arribas J, Andrade-Villanueva J, DiPerri G, van Lunzen J, Koenig E . Switching from tenofovir disoproxil fumarate to tenofovir alafenamide in antiretroviral regimens for virologically suppressed adults with HIV-1 infection: a randomised, active-controlled, multicentre, open-label, phase 3, non-inferiority study. Lancet Infect Dis. 2015; 16(1):43-52. DOI: 10.1016/S1473-3099(15)00348-5. View

Masia M, Padilla S, Robledano C, Lopez N, Ramos J, Gutierrez F . Early changes in parathyroid hormone concentrations in HIV-infected patients initiating antiretroviral therapy with tenofovir. AIDS Res Hum Retroviruses. 2011; 28(3):242-6. DOI: 10.1089/AID.2011.0052. View

Bernardino J, Mocroft A, Mallon P, Wallet C, Gerstoft J, Russell C . Bone mineral density and inflammatory and bone biomarkers after darunavir-ritonavir combined with either raltegravir or tenofovir-emtricitabine in antiretroviral-naive adults with HIV-1: a substudy of the NEAT001/ANRS143 randomised trial. Lancet HIV. 2015; 2(11):e464-73. DOI: 10.1016/S2352-3018(15)00181-2. View

Brown T, McComsey G, King M, Qaqish R, Bernstein B, da Silva B . Loss of bone mineral density after antiretroviral therapy initiation, independent of antiretroviral regimen. J Acquir Immune Defic Syndr. 2009; 51(5):554-61. DOI: 10.1097/QAI.0b013e3181adce44. View

Yong M, Elliott J, Woolley I, Hoy J . Low CD4 count is associated with an increased risk of fragility fracture in HIV-infected patients. J Acquir Immune Defic Syndr. 2011; 57(3):205-10. DOI: 10.1097/QAI.0b013e31821ecf4c. View

Woodward C, Hall A, WILLIAMS I, Madge S, Copas A, Nair D . Tenofovir-associated renal and bone toxicity. HIV Med. 2009; 10(8):482-7. DOI: 10.1111/j.1468-1293.2009.00716.x. View

Hamzah L, Tiraboschi J, Iveson H, Toby M, Mant C, Cason J . Effects on vitamin D, bone and the kidney of switching from fixed-dose tenofovir disoproxil fumarate/emtricitabine/efavirenz to darunavir/ritonavir monotherapy: a randomized, controlled trial (MIDAS). Antivir Ther. 2015; 21(4):287-96. DOI: 10.3851/IMP3000. View

Madruga J, Cassetti I, Suleiman J, Etzel A, Zhong L, Holmes C . The safety and efficacy of switching stavudine to tenofovir df in combination with lamivudine and efavirenz in hiv-1-infected patients: three-year follow-up after switching therapy. HIV Clin Trials. 2007; 8(6):381-90. DOI: 10.1310/hct0806-381. View

10.

Hall A, Edwards S, Lapsley M, Connolly J, Chetty K, OFarrell S . Subclinical tubular injury in HIV-infected individuals on antiretroviral therapy: a cross-sectional analysis. Am J Kidney Dis. 2009; 54(6):1034-42. DOI: 10.1053/j.ajkd.2009.07.012. View

11.

Mateo L, Holgado S, Marinoso M, Perez-Andres R, Bonjoch A, Romeu J . Hypophosphatemic osteomalacia induced by tenofovir in HIV-infected patients. Clin Rheumatol. 2014; 35(5):1271-9. DOI: 10.1007/s10067-014-2627-x. View

12.

Kasonde M, Niska R, Rose C, Henderson F, Segolodi T, Turner K . Bone mineral density changes among HIV-uninfected young adults in a randomised trial of pre-exposure prophylaxis with tenofovir-emtricitabine or placebo in Botswana. PLoS One. 2014; 9(3):e90111. PMC: 3953113. DOI: 10.1371/journal.pone.0090111. View

13.

Kinai E, Hanabusa H . Progressive renal tubular dysfunction associated with long-term use of tenofovir DF. AIDS Res Hum Retroviruses. 2009; 25(4):387-94. DOI: 10.1089/aid.2008.0202. View

14.

Gupta S, Anderson A, Ebrahimi R, Fralich T, Graham H, Scharen-Guivel V . Fanconi syndrome accompanied by renal function decline with tenofovir disoproxil fumarate: a prospective, case-control study of predictors and resolution in HIV-infected patients. PLoS One. 2014; 9(3):e92717. PMC: 3961428. DOI: 10.1371/journal.pone.0092717. View

15.

Lee W, He G, Eisenberg E, Cihlar T, Swaminathan S, Mulato A . Selective intracellular activation of a novel prodrug of the human immunodeficiency virus reverse transcriptase inhibitor tenofovir leads to preferential distribution and accumulation in lymphatic tissue. Antimicrob Agents Chemother. 2005; 49(5):1898-906. PMC: 1087627. DOI: 10.1128/AAC.49.5.1898-1906.2005. View

16.

Sharma A, Shi Q, Hoover D, Anastos K, Tien P, Young M . Increased Fracture Incidence in Middle-Aged HIV-Infected and HIV-Uninfected Women: Updated Results From the Women's Interagency HIV Study. J Acquir Immune Defic Syndr. 2015; 70(1):54-61. PMC: 4557627. DOI: 10.1097/QAI.0000000000000674. View

17.

Bloch M, Tong W, Hoy J, Baker D, Lee F, Richardson R . Switch from tenofovir to raltegravir increases low bone mineral density and decreases markers of bone turnover over 48 weeks. HIV Med. 2014; 15(6):373-80. DOI: 10.1111/hiv.12123. View

18.

Rodriguez-Novoa S, Labarga P, Soriano V, Egan D, Albalater M, Morello J . Predictors of kidney tubular dysfunction in HIV-infected patients treated with tenofovir: a pharmacogenetic study. Clin Infect Dis. 2009; 48(11):e108-16. DOI: 10.1086/598507. View

19.

Brown T, Hoy J, Borderi M, Guaraldi G, Renjifo B, Vescini F . Recommendations for evaluation and management of bone disease in HIV. Clin Infect Dis. 2015; 60(8):1242-51. PMC: 4400413. DOI: 10.1093/cid/civ010. View

20.

Van Rompay K, Brignolo L, Meyer D, Jerome C, Tarara R, Spinner A . Biological effects of short-term or prolonged administration of 9-[2-(phosphonomethoxy)propyl]adenine (tenofovir) to newborn and infant rhesus macaques. Antimicrob Agents Chemother. 2004; 48(5):1469-87. PMC: 400569. DOI: 10.1128/AAC.48.5.1469-1487.2004. View